Nanobiotix (NASDAQ:NBTX) Shares Gap Up Following Analyst Upgrade

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s stock price gapped up before the market opened on Monday after Guggenheim raised their price target on the stock from $8.00 to $26.00. The stock had previously closed at $20.85, but opened at $22.36. Guggenheim currently has a buy rating on the stock. Nanobiotix shares last traded at $22.1650, with a volume of 2,737 shares changing hands.

Several other equities research analysts also recently weighed in on the stock. TD Cowen started coverage on shares of Nanobiotix in a research note on Friday. They issued a “buy” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday, January 22nd. Leerink Partners reissued an “outperform” rating on shares of Nanobiotix in a research note on Tuesday, November 25th. HC Wainwright restated a “buy” rating on shares of Nanobiotix in a research report on Tuesday, November 4th. Finally, Wall Street Zen upgraded Nanobiotix to a “hold” rating in a report on Saturday, October 25th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Institutional Investors Weigh In On Nanobiotix

A hedge fund recently bought a new stake in Nanobiotix stock. Optiver Holding B.V. purchased a new position in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 5,356 shares of the company’s stock, valued at approximately $101,000. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Nanobiotix Stock Up 13.0%

The stock’s fifty day simple moving average is $21.70 and its 200 day simple moving average is $17.60.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.